1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
1.8. Key benefits to the stakeholder
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Process
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. Analyst View
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. ANTI-PSYCHOTIC DRUGS MARKET BY THERAPEUTIC CLASS
5.1. Introduction
5.2. First-generation
5.2.1. Market opportunities and trends
5.2.2. Growth prospects
5.2.3. Geographic lucrativeness
5.3. Second-generation
5.3.1. Market opportunities and trends
5.3.2. Growth prospects
5.3.3. Geographic lucrativeness
6. ANTI-PSYCHOTIC DRUGS MARKET BY DISTRIBUTION CHANNEL
6.1. Introduction
6.2. Hospital Pharmacies
6.2.1. Market opportunities and trends
6.2.2. Growth prospects
6.2.3. Geographic lucrativeness
6.3. Retail Pharmacies
6.3.1. Market opportunities and trends
6.3.2. Growth prospects
6.3.3. Geographic lucrativeness
6.4. Online Pharmacies
6.4.1. Market opportunities and trends
6.4.2. Growth prospects
6.4.3. Geographic lucrativeness
7. ANTI-PSYCHOTIC DRUGS MARKET BY APPLICATION
7.1. Introduction
7.2. Schizophrenia
7.2.1. Market opportunities and trends
7.2.2. Growth prospects
7.2.3. Geographic lucrativeness
7.3. Dementia
7.3.1. Market opportunities and trends
7.3.2. Growth prospects
7.3.3. Geographic lucrativeness
7.4. Bipolar Disorder
7.4.1. Market opportunities and trends
7.4.2. Growth prospects
7.4.3. Geographic lucrativeness
7.5. Depression
7.5.1. Market opportunities and trends
7.5.2. Growth prospects
7.5.3. Geographic lucrativeness
7.6. Others
7.6.1. Market opportunities and trends
7.6.2. Growth prospects
7.6.3. Geographic lucrativeness
8. ANTI-PSYCHOTIC DRUGS MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Therapeutic Class
8.2.2. By Distribution Channel
8.2.3. By Application
8.2.4. By Country
8.2.4.1. United States
8.2.4.1.1. Market Trends and Opportunities
8.2.4.1.2. Growth Prospects
8.2.4.2. Canada
8.2.4.2.1. Market Trends and Opportunities
8.2.4.2.2. Growth Prospects
8.2.4.3. Mexico
8.2.4.3.1. Market Trends and Opportunities
8.2.4.3.2. Growth Prospects
8.3. South America
8.3.1. By Therapeutic Class
8.3.2. By Distribution Channel
8.3.3. By Application
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.1.1. Market Trends and Opportunities
8.3.4.1.2. Growth Prospects
8.3.4.2. Argentina
8.3.4.2.1. Market Trends and Opportunities
8.3.4.2.2. Growth Prospects
8.3.4.3. Others
8.3.4.3.1. Market Trends and Opportunities
8.3.4.3.2. Growth Prospects
8.4. Europe
8.4.1. By Therapeutic Class
8.4.2. By Distribution Channel
8.4.3. By Application
8.4.4. By Country
8.4.4.1. UK
8.4.4.1.1. Market Trends and Opportunities
8.4.4.1.2. Growth Prospects
8.4.4.2. Germany
8.4.4.2.1. Market Trends and Opportunities
8.4.4.2.2. Growth Prospects
8.4.4.3. France
8.4.4.3.1. Market Trends and Opportunities
8.4.4.3.2. Growth Prospects
8.4.4.4. Spain
8.4.4.4.1. Market Trends and Opportunities
8.4.4.4.2. Growth Prospects
8.4.4.5. Others
8.4.4.5.1. Market Trends and Opportunities
8.4.4.5.2. Growth Prospects
8.5. Middle East and Africa
8.5.1. By Therapeutic Class
8.5.2. By Distribution Channel
8.5.3. By Application
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.1.1. Market Trends and Opportunities
8.5.4.1.2. Growth Prospects
8.5.4.2. UAE
8.5.4.2.1. Market Trends and Opportunities
8.5.4.2.2. Growth Prospects
8.5.4.3. Israel
8.5.4.3.1. Market Trends and Opportunities
8.5.4.3.2. Growth Prospects
8.5.4.4. Others
8.5.4.4.1. Market Trends and Opportunities
8.5.4.4.2. Growth Prospects
8.6. Asia Pacific
8.6.1. By Therapeutic Class
8.6.2. By Distribution Channel
8.6.3. By Application
8.6.4. By Country
8.6.4.1. Japan
8.6.4.1.1. Market Trends and Opportunities
8.6.4.1.2. Growth Prospects
8.6.4.2. China
8.6.4.2.1. Market Trends and Opportunities
8.6.4.2.2. Growth Prospects
8.6.4.3. India
8.6.4.3.1. Market Trends and Opportunities
8.6.4.3.2. Growth Prospects
8.6.4.4. South Korea
8.6.4.4.1. Market Trends and Opportunities
8.6.4.4.2. Growth Prospects
8.6.4.5. Indonesia
8.6.4.5.1. Market Trends and Opportunities
8.6.4.5.2. Growth Prospects
8.6.4.6. Thailand
8.6.4.6.1. Market Trends and Opportunities
8.6.4.6.2. Growth Prospects
8.6.4.7. Others
8.6.4.7.1. Market Trends and Opportunities
8.6.4.7.2. Growth Prospects
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisition, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. AstraZeneca Plc.
10.2. Pfizer, Inc
10.3. Alkermes Plc.
10.4. Eli Lilly and Company
10.5. Bristol-Myers Squibb Company
10.6. Johnson and Johnson
10.7. Teva Pharmaceutical Industries Ltd.
10.8. Otsuka Holdings Co. Ltd.
10.9. AbbVie, Inc.